# A Trial of HRS-6768 in Patients With Advanced Solid Tumors

Source: https://nuclide.cc/trials/nct06925581/  
Nuclide record `nct06925581` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HRS-6768 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Trial of HRS-6768 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06925581 by Jiangsu HengRui Medicine Co., Ltd., with 84 participants planned, started 2025-04-24 and due to reach its primary completion in 2026-04. Interventions recorded: HRS-6768.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06925581
- Phase: 1/2
- Setting: A Phase I/II Clinical Trial to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-6768 in the Treatment of Patients With Advanced Solid Tumors
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT06925581: https://clinicaltrials.gov/study/NCT06925581

---
JSON: https://nuclide.cc/api/v1/entities/nct06925581.json